Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

06 Aug 2026, 06:29 by Teresa Graham · The Cerbat Gem

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $66.0556.

BMY has been the subject of a number of recent research reports. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday. They issued a “buy” rating and a $75.00 price objective for the company. Royal Bank Of Canada upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Wednesday. They issued an “overweight” rating for the company. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, July 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st.

View Our Latest Analysis on BMY

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Argus upgraded Bristol Myers Squibb (BMY) from “hold” to “buy” and set a $75 price target, implying meaningful upside from the stock’s recent level. The upgrade provides support for the investment case despite the merger speculation fading. Argus upgrade report
Neutral Sentiment: Berenberg maintained a “hold” rating on BMY, indicating that some analysts remain cautious even after the stock reached a new 52-week high. Berenberg maintains hold rating
Neutral Sentiment: BMY’s recent rally and 52-week-high performance have prompted investors to evaluate whether additional gains are justified by the company’s fundamentals and valuation, rather than by potential merger activity. BMY 52-week-high analysis
Negative Sentiment: Reuters reported that a senior source denied any ongoing merger discussions between AstraZeneca and Bristol Myers Squibb. The news reverses earlier reports that had fueled expectations for a transformative deal, likely pressuring BMY as investors remove any merger premium from the shares. Reuters report denying AstraZeneca-Bristol Myers discussions

Institutional Trading of Bristol Myers Squibb

A number of large investors have recently bought and sold shares of BMY. Norges Bank bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $1,947,272,000. AQR Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after purchasing an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC raised its position in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Finally, Man Group plc boosted its stake in Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 3.3%

Bristol Myers Squibb stock opened at $63.73 on Thursday. The business has a 50 day moving average price of $58.41 and a two-hundred day moving average price of $58.53. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.10. The stock has a market cap of $130.18 billion, a price-to-earnings ratio of 14.04, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts forecast that Bristol Myers Squibb will post 6.97 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.